2Q Revenues: $6.2 million (+19%)
2Q Loss: $4.6 million (earnings were $35.4 million 2Q12)
YTD Revenues: $11.7 million (+17%)
YTD Loss: $4.3 million (loss of $35.1 million YTD12)
Comments: Growth in the quarter was primarily due to a 26% increase in prescription sales to $3.9 million. Contract sales and royalties increased 7% to $2.2 million in the quarter. R&D costs increased 108% to $0.4 million, due to a Generic Drug User Fee Act (GDUFA) fee of $52,000 in the quarter.